MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

Alzheimer's Disease Clinical Trial

Official title:

MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00362024
• Other study ID #: 0952-004
• Secondary ID: 2006_026
• Status: Terminated
• Phase: Phase 2
• First received: August 8, 2006
• Last updated: May 13, 2016
• Start date: November 2006
• Est. completion date: November 2007

Study information

• Verified date: May 2016
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 24
• Est. completion date: November 2007
• Est. primary completion date: November 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Male or females

• Age >/= 55 years, With mild-to-moderate AD, with MMSE between 18 and 26, inclusive, MHIS score </= 4, Global CDR score of 1 or 2

• Who have a reliable informant/caregiver to accompany patient to all clinic visits

• If using a symptomatic AD treatments, patients must be on stable dose for >/= 6 months

Exclusion Criteria:

• Patients must not be living in nursing home or skilled nursing facility

• Patients must not have current evidence and/or history of Crohn's disease, ulcerative colitis, proctitis, GI bleeding, mesenteric arteritis

• Patients must not have current evidence and/or history of poorly-controlled hypertension, clinically significant cardiac arrhythmia, angina, or CHF

• Patients must not have current evidence and/or history of a psychotic disorder or major untreated depressive disorder

• Patients must not have current evidence and/or history of stroke or multiple lacunar infarcts, or neurological or neurodegenerative disorder (other than AD)

• Various concomitant therapy restrictions

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Drug:
• MK0952

• Comparator: Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.